Researchers have developed miniature magnetic robots that mimic fish behavior, working together as coordinated swarms to deliver drugs precisely and efficiently to tissue. The breakthrough could transform treatment of conditions where individual tiny robots lack sufficient coverage area for effective therapy.

This study introduces an innovative cloud-based Genome-Wide Association Study (GWAS) platform​that addresses critical challenges in genomic research, including inefficient data access, high computational demands, and complex data integration. By leveraging Kubernetes-based distributed architecture and hybrid storage systems, the platform integrates multi-omics data (neuroimaging, proteomics, microbiome, metabolomics, immunology) from major databases (GWAS Catalog, UK Biobank, FinnGen) encompassing​40,000+ phenotypes. A key innovation is the ​FastGWASR R package, enabling seamless Mendelian randomization, drug target validation, and multi-omics analyses. Performance evaluations demonstrate​sub-second data extraction,​>99% reduction in local storage needs, and significantly lower hardware requirements​compared to traditional methods. The platform successfully processed large-scale analyses (e.g., MR-PheWAS, multi-omics integration) with comparable scientific accuracy but dramatically improved efficiency. Case studies validated its effectiveness in metabolite-diabetes causal analysis, PCSK9 drug target validation, and gut microbiome-inflammation network analysis. The​cloud ecosystem democratizes genomic research, reducing barriers for resource-limited institutions and fostering interdisciplinary collaboration. Its secure, scalable, and user-friendly design accelerates discoveries in precision medicine, from disease risk prediction to drug development. Future enhancements will expand data diversity, optimize algorithms, and strengthen ecosystem interoperability, positioning the platform as a transformative force in global genomics and personalized healthcare.

A new review from Beijing Chest Hospital, Capital Medical University, systematically expounds the dual role of DNA repair core protein Rad51 in tumors. This article reveals that Rad51 not only maintains genomic stability through homologous recombination repair, but its overexpression is also closely related to chemotherapy, radiotherapy and PARP inhibitor resistance in various cancers. Most importantly, the review delves deeply into how Rad51 shapes the tumor immune microenvironment by regulating the cGAS-STING pathway, influencing neoantigen generation and PD-L1 expression, providing a new theoretical basis for the anti-cancer strategy of combining Rad51 with immune checkpoint inhibitors.